Consensus Verastem, Inc.

Stocks

VSTM

US92337C2035

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-03 EDT			5-day change	1st Jan Change
7.980 ^USD	-0.50%		+7.98%	+3.37%

08-11	Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating	MT
08-07	Verastem, Inc. Amends Note Purchase Agreement to Establish New Series of Senior Secured Revenue Notes Up to $75 Million	CI

Evolution of the Average Target: Verastem, Inc.

Evolution of the Target Price: Verastem, Inc.

Changes in Analyst Recommendations: Verastem, Inc.

5017791b9eec00ea248e9d06.d22JgURytVDv1oTcgUYnVapccEigPsQZ4vnHF1JdR7c.BDXq0QoljADWvMCf9X5meM8VNybqdaNxsrSMOggWdecOIPDiLDXRYN2F4w~5f47decfc4644aa745da2538a0f4478e

Analysts' recommendations: Verastem, Inc.

08-11	Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating	MT
07-07	RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating	MT
06-24	Verastem's VS-7375 Update Reiterates Potential in US Patients, RBC Says	MT
05-14	Mizuho Adjusts Price Target on Verastem to $14 From $16, Maintains Outperform Rating	MT
04-29	Mizuho Securities Keeps Verastem Price Target to $16, Maintains Outperform Rating	MT
04-29	Mizuho Securities Adjusts Verastem Price Target to $16 From $18, Maintains Outperform Rating	MT
01-08	RBC Raises Price Target on Verastem to $15 From $14, Keeps Outperform, Speculative Risk	MT
11-05	RBC Capital Adjusts Verastem Price Target to $14 From $13, Maintains Outperform Rating	MT
25-10-19	Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma	CI
25-08-26	B. Riley Raises Price Target on Verastem to $16 From $13, Keeps Buy Rating	MT
25-08-15	Mizuho Securities Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating	MT
25-08-08	RBC Raises Price Target on Verastem to $13 From $12, Keeps Outperform, Speculative Risk	MT
25-06-25	RBC Cuts Price Target on Verastem to $12 From $16, Keeps Outperform, Speculative Risk	MT
25-05-09	B. Riley Adjusts Verastem Price Target to $13 From $12, Maintains Buy Rating	MT
25-05-09	Mizuho Adjusts Price Target on Verastem to $16 From $8, Maintains Outperform Rating	MT
25-05-09	RBC Raises Price Target on Verastem to $16 From $14, Keeps Outperform, Speculative Risk	MT
25-04-28	B. Riley Adjusts Verastem Price Target to $12 From $9, Maintains Buy Rating	MT
25-04-10	Jefferies Initiates Verastem at Buy With $15 Price Target	MT
25-04-08	Mizuho Securities Adjusts Verastem Price Target to $8 From $9, Maintains Outperform Rating	MT
25-03-21	RBC Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating	MT
25-01-31	B. Riley Adjusts Verastem's Price Target to $9 From $7, Maintains Buy Rating	MT
25-01-07	RBC Raises Price Target on Verastem to $16 From $13, Keeps Outperform, Speculative Risk	MT
24-12-31	BTIG Raises Price Target on Verastem to $20 From $13, Keeps Buy Rating	MT
24-12-18	Mizuho Raises Price Target on Verastem to $9 From $7, Keeps Outperform Rating	MT
24-09-30	Guggenheim Initiates Coverage on Verastem With Buy Rating, $13 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	VERASTEM, INC.					+87.03%
	WUXI APPTEC CO., LTD.					+19.41%
	ARGENX SE					+9.33%
	INSMED INCORPORATED					+58.08%
	WUXI BIOLOGICS (CAYMAN) INC.					+16.48%
	BIONTECH SE					+15.93%
	GENMAB A/S					+11.59%
	PHARMAESSENTIA CORPORATION					+7.07%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+25.44%
	EXELIXIS, INC.					-8.27%
	Average					+24.21%
	Weighted average by Cap.					+18.04%